Last updated on December 2016

Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema


Brief description of study

This 2-part study will evaluate the safety and efficacy of an oral treatment, BCX7353, in preventing angioedema attacks in subjects with hereditary angioedema (HAE). In Part 1 of the study, eligible subjects will be randomized to receive oral BCX7353 or placebo for 4 weeks. Assuming successful completion of Part 1, additional subjects will be randomized in Part 2 to one of 2 lower doses of BCX7353 or placebo. The study will compare the number of acute attacks in each treatment group, as well as a number of other clinical and pharmacologic outcomes, and the safety and tolerability of each dose of BCX7353 compared to placebo.

Clinical Study Identifier: NCT02870972

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Clinical Trials

Adelaide, Australia
  Connect »

Clinical Trials

Campbelltown, Australia
  Connect »

Clinical Trials

Quebec City, Canada
  Connect »

Clinical Trials

Frankfurt, Germany
  Connect »

Clinical Trials

Budapest, Hungary
  Connect »

Clinical Trials

Skopje, Macedonia, The Former Yugoslav Republic of
  Connect »

Clinical Trials

Zürich, Switzerland
  Connect »

Clinical Trials

Brimingham, United Kingdom
  Connect »

Clinical Trials

Bristol, United Kingdom
  Connect »

Clinical Trials

London, United Kingdom
  Connect »

Clinical Trials

Oxford, United Kingdom
  Connect »

Clinical Trials

Southampton, United Kingdom
  Connect »